Literature DB >> 8219202

High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.

K Bhalla1, A M Ibrado, E Tourkina, C Tang, S Grant, G Bullock, Y Huang, V Ponnathpur, M E Mahoney.   

Abstract

Mitoxantrone has been shown in vitro to exhibit a steep dose-response relationship with respect to the clonogenic survival of acute myeloid leukemia cells. In this report, we show that 1-hour exposure of human myeloid leukemia HL-60 and KG-1 cells to mitoxantrone concentrations ranging between 0.1 and 10.0 mumol/L induced internucleosomal DNA fragmentation of approximately 200-bp integer multiples, characteristic of cells undergoing programmed cell death (PCD) or apoptosis. Mitoxantrone-mediated PCD was associated with a steep inhibition of the clonogenic survival of the leukemic cells. In addition, intracellularly, mitoxantrone-induced PCD was associated with a marked induction of c-jun and significant repression of c-myc and BCL-2 oncogenes. Pretreatment with the protein kinase C stimulator phorbol myristate acetate enhanced mitoxantrone-induced internucleosomal DNA fragmentation, whereas protein kinase C inhibitors staurosporine and H7 had no effect. These findings suggest that PCD is a potential mechanism underlying the steep dose-response relationship of mitoxantrone to the inhibition of clonogenic survival of acute myeloid leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219202

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Induction of apoptosis in human lymphoblastoid cells by kaempferol 3-O-β-isorhamninoside and rhamnocitrin 3-O-β-isorhamninoside from Rhamnus alaternus L. (Rhamnaceae).

Authors:  W Bhouri; I Bouhlel; J Boubaker; S Kilani; K Ghedira; L Chekir Ghedira
Journal:  Cell Prolif       Date:  2011-06       Impact factor: 6.831

2.  Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Authors:  Ramesh Balusu; Warren Fiskus; Rekha Rao; Daniel G Chong; Srilatha Nalluri; Uma Mudunuru; Hongwei Ma; Lei Chen; Sreedhar Venkannagari; Kyungsoo Ha; Sunil Abhyankar; Casey Williams; Joseph McGuirk; Hanna Jean Khoury; Celalettin Ustun; Kapil N Bhalla
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

3.  Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.

Authors:  A Feofanov; S Sharonov; F Fleury; I Kudelina; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

4.  Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

Authors:  A Chan; F X Weilbach; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

5.  Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells.

Authors:  Zhao-Zhe Liu; Jin Zhu; Bo Sun; Shu Liu; Shuo Geng; Xia Liu; Chang-Ling Li
Journal:  Mol Cell Biochem       Date:  2007-08-23       Impact factor: 3.396

Review 6.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

7.  1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation.

Authors:  S Ray; V Ponnathpur; Y Huang; C Tang; M E Mahoney; A M Ibrado; G Bullock; K Bhalla
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis.

Authors:  Sylvia Mansilla; Benjamin Piña; José Portugal
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

9.  Cell death signaling and anticancer therapy.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Erika Vacchelli; Guido Kroemer
Journal:  Front Oncol       Date:  2011-05-03       Impact factor: 6.244

10.  Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.

Authors:  Sucheta Jagan; Laura A Paganessi; Robin R Frank; Parameswaran Venugopal; Melissa Larson; Kent W Christopherson
Journal:  Adv Hematol       Date:  2012-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.